Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing
Abstract The purpose of this review is to explore how metabolomics can help uncover new biomarkers and mechanisms for cardiovascular ageing. Cardiovascular ageing refers to cardiovascular structural and functional alterations that occur with chronological ageing and that can lead to the development...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-06-01
|
| Series: | ESC Heart Failure |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ehf2.13274 |
| _version_ | 1797976478666719232 |
|---|---|
| author | Angela S. Koh Jean‐Paul Kovalik |
| author_facet | Angela S. Koh Jean‐Paul Kovalik |
| author_sort | Angela S. Koh |
| collection | DOAJ |
| description | Abstract The purpose of this review is to explore how metabolomics can help uncover new biomarkers and mechanisms for cardiovascular ageing. Cardiovascular ageing refers to cardiovascular structural and functional alterations that occur with chronological ageing and that can lead to the development of cardiovascular disease. These alterations, which were previously only detectable on tissue histology or corroborated on blood samples, are now detectable with modern imaging techniques. Despite the emergence of powerful new imaging tools, clinical investigation into cardiovascular ageing is challenging because ageing is a life course phenomenon involving known and unknown risk factors that play out in a dynamic fashion. Metabolomic profiling measures large numbers of metabolites with diverse chemical properties. Metabolomics has the potential to capture changes in biochemistry brought about by pathophysiologic processes as well as by normal ageing. When combined with non‐invasive cardiovascular imaging tools, metabolomics can be used to understand pathological consequences of cardiovascular ageing. This review will summarize previous metabolomics and imaging studies in cardiovascular ageing. These methods may be a clinically relevant and novel approach to identify mechanisms of cardiovascular ageing and formulate or personalize treatment strategies. |
| first_indexed | 2024-04-11T04:51:32Z |
| format | Article |
| id | doaj.art-d9019bc2123148d2b6a8e08f68da77a9 |
| institution | Directory Open Access Journal |
| issn | 2055-5822 |
| language | English |
| last_indexed | 2024-04-11T04:51:32Z |
| publishDate | 2021-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | ESC Heart Failure |
| spelling | doaj.art-d9019bc2123148d2b6a8e08f68da77a92022-12-27T03:53:06ZengWileyESC Heart Failure2055-58222021-06-01831738175010.1002/ehf2.13274Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageingAngela S. Koh0Jean‐Paul Kovalik1National Heart Centre Singapore 5 Hospital Drive Singapore 169609 SingaporeDuke‐NUS Medical School Singapore SingaporeAbstract The purpose of this review is to explore how metabolomics can help uncover new biomarkers and mechanisms for cardiovascular ageing. Cardiovascular ageing refers to cardiovascular structural and functional alterations that occur with chronological ageing and that can lead to the development of cardiovascular disease. These alterations, which were previously only detectable on tissue histology or corroborated on blood samples, are now detectable with modern imaging techniques. Despite the emergence of powerful new imaging tools, clinical investigation into cardiovascular ageing is challenging because ageing is a life course phenomenon involving known and unknown risk factors that play out in a dynamic fashion. Metabolomic profiling measures large numbers of metabolites with diverse chemical properties. Metabolomics has the potential to capture changes in biochemistry brought about by pathophysiologic processes as well as by normal ageing. When combined with non‐invasive cardiovascular imaging tools, metabolomics can be used to understand pathological consequences of cardiovascular ageing. This review will summarize previous metabolomics and imaging studies in cardiovascular ageing. These methods may be a clinically relevant and novel approach to identify mechanisms of cardiovascular ageing and formulate or personalize treatment strategies.https://doi.org/10.1002/ehf2.13274AgeingCardiovascular diseaseMetabolomicsCardiovascular imaging |
| spellingShingle | Angela S. Koh Jean‐Paul Kovalik Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing ESC Heart Failure Ageing Cardiovascular disease Metabolomics Cardiovascular imaging |
| title | Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing |
| title_full | Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing |
| title_fullStr | Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing |
| title_full_unstemmed | Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing |
| title_short | Metabolomics and cardiovascular imaging: a combined approach for cardiovascular ageing |
| title_sort | metabolomics and cardiovascular imaging a combined approach for cardiovascular ageing |
| topic | Ageing Cardiovascular disease Metabolomics Cardiovascular imaging |
| url | https://doi.org/10.1002/ehf2.13274 |
| work_keys_str_mv | AT angelaskoh metabolomicsandcardiovascularimagingacombinedapproachforcardiovascularageing AT jeanpaulkovalik metabolomicsandcardiovascularimagingacombinedapproachforcardiovascularageing |